Increased bradykinin and "normal" angiotensin peptide levels in diabetic Sprague-Dawley and transgenic (mRen-2)27 rats

Kidney International

Volumn 56, Issue 1, 1999, Pages 211-221

  Campbell, Duncan J ^a   Kelly, Darren J ^a   Wilkinson Berka, Jennifer L ^a   Cooper, Mark E ^a   Skinner, Sandford L ^a  

^a NONE

Author keywords

Angiotensin converting enzyme; Diabetic nephropathy; Endopeptidase; Hypertension; Prorenin

Indexed keywords

ANGIOTENSIN; BRADYKININ; CITRIC ACID; STREPTOZOCIN;

ANGIOTENSIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; FEMALE; HYPERGLYCEMIA; HYPERTENSION; KIDNEY FAILURE; NONHUMAN; PRIORITY JOURNAL; RAT; TRANSGENIC ANIMAL;

EID: 0033038821     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.00519.x     Document Type: Article

References (47)

1. STALDER G, SCHMID R: Severe functional disorders of glomerular capillaries and renal hemodynamics in treated diabetes mellitus during childhood. Ann Pediatr (Paris) 193:129-138, 1959
2. MOGENSEN CE: Glomerular filtration rate and renal plasma flow in short-term and long-term juvenile diabetes mellitus. Scand J Clin Lab Invest 28:91-100, 1971
3. CHRISTIANSEN JS, GAMMELGAARD J, FRANDSEN M, PARVING H-H: Increased kidney size, glomerular filtration rate and renal plasma flow in short-term insulin-dependent diabetics. Diabetologia 20:451-456, 1981
4. CHRISTIANSEN JS, GAMMELGAARD S, TRONIER B, SVENDSEN PA, PARVING H-H: Kidney function and size in diabetics before and during initial insulin treatment. Kidney Int 21:683-688, 1982
5. HOSTETTER TH, TROY JL, BRENNER BM: Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int 19:410-415, 1981
6. JENSEN PK, CHRISTIANSEN JS, STEVEN K, PARVING H-H: Renal function in streptozotocin-diabetic rats. Diabetologia 21:409-414, 1981
7. ZATZ R, MEYER TW, RENNKE HG, BRENNER BM: Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci USA 82:5963-5967, 1985
8. BHOOLA KD, FIGUEROA CD, WORTHY K: Bioregulation of kinins: Kallikreins, kininogens, and kininases. Pharmacol Rev 44:1-80, 1992
9. HALL JE, GUYTON AC, JACKSON TE, COLEMAN TG, LOHMEIER TE, TRIPPODO NC: Control of glomerular filtration rate by renin-angiotensin system. Am J Physiol 233:F366-F372, 1977
10. WOLF G, ZIYADEH FN: The role of angiotensin II in diabetic nephropathy: Emphasis on nonhemodynamic mechanisms. Am J Kidney Dis 29:153-163, 1997
11. MARRE M, JEUNEMAITRE X, GALLOIS Y, RODIER M, CHATELLIER G, SERT C, DUSSELIER L, KAHAL Z, CHAILLOUS L, HALIMI S, MULLER A, SACKMANN H, BAUDUCEAU B, BLED F, PASSA P, ALHENC-GELAS F: Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes. J Clin Invest 99:1585-1595, 1997
12. FOGARTY DG, HARRON JC, HUGHES AE, NEVIN NC, DOHERTY CC, MAXWELL AP: A molecular variant of angiotensinogen is associated with diabetic nephropathy in IDDM. Diabetes 45:1204-1208, 1996
13. O'DRISCOLL G, GREEN D, RANKIN J, STANTON K, TAYLOR R: Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J Clin Invest 100:678-684, 1997
14. LEWIS EJ, HUNSICKER LG, BAIN RP, ROHDE RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
15. PARVING H-H, ROSSING P, HOMMEL E, SMIDT UM: Angiotensin-converting enzyme inhibition in diabetic nephropathy: Ten years' experience. Am J Kidney Dis 26:99-107, 1995
16. ZATZ R, DÜNN R, MEYER TW, ANDERSON S, RENNKE HG, BRENNER BM, TROY JL, DEGRAPHENRIED RL, NODDIN JL, NUNN AW, SANDSTROM D: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77:1925-1930, 1986
17. ALLEN TJ, CAO ZM, YOUSSEF S, HULTHEN UL, COOPER ME: Role of angiotensin II and bradykinin in experimental diabetic nephropathy: Functional and structural studies. Diabetes 46:1612-1618, 1997
18. RUMBLE JR, KOMERS R, COOPER ME: Kinins or nitric oxide, or both, are involved in the antitrophic effects of angiotensin converting enzyme inhibitors on diabetes-associated mesenteric vascular hypertrophy in the rat. J Hypertens 14:601-607, 1996
19. CAMPBELL DJ, RONG P, KLADIS A, REES B, SKINNER SL: Angioten-sin and bradykinin peptides in the TGR (mRen-2)27 rat. Hypertension 25:1014-1020, 1995
20. KELLY DJ, WILKINSON-BERKA JL, ALLEN TJ, COOPER ME, SKINNER SL: A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). Kidney Int 54:343-352, 1998
21. CAMPBELL DJ, KLADIS A, DUNCAN A-M: Nephrectomy, converting enzyme inhibition and angiotensin peptides. Hypertension 22:513-522, 1993
22. HUI KY, HOLTZMAN EJ, QUINONES MA, HOLLENBERG NK, HABER E: Design of rat renin inhibitory peptides. J Med Chem 31:1679-1686, 1988
23. CAMPBELL DJ, LAWRENCE AC, KLADIS A, DUNCAN A-M: Strategies for measurement of angiotensin and bradykinin peptides and their metabolites in central nervous system and other tissues, in Methods in Neurosciences (vol 23) Peptidases and Neuropeptide Processing, edited by SMITH AI, Orlando, Academic Press, 1995, pp 328-343
24. CAMPBELL DJ, KLADIS A, DUNCAN A-M: Bradykinin peptides in kidney, blood, and other tissues of the rat. Hypertension 21:155-165, 1993
25. CAMPBELL DJ, LAWRENCE AC, TOWRIE A, KLADIS A, VALENTIJN AJ: Differential regulation of angiotensin peptide levels in plasma and kidney of the rat. Hypertension 18:763-773, 1991
26. FRIEDLAND J, SILVERSTEIN E: A sensitive fluorometric assay for serum angiotensin-converting enzyme. Am J Clin Pathol 66:416-424, 1976
27. YANDLE T, RICHARDS M, SMITH M, CHARLES C, LIVESEY J, ESPINER E: Assay of endopeptidase-24.11 activity in plasma applied to in vivo studies of endopeptidase inhibitors. Clin Chem 38:1785-1791, 1992
28. HARVEY JN, JAFFA AA, MARGOLIUS HS, MAYFIELD RK: Renal kalli-krein and hemodynamic abnormalities of diabetic kidney. Diabetes 39:299-304, 1990
29. HARVEY JN, EDMUNDSON AW, JAFFA AA, MARTIN LL, MAYFIELD RK: Renal excretion of kallikrein and eicosanoids in patients with type 1 (insulin-dependent) diabetes mellitus: Relationship to glomerular and tubular function. Diabetologia 35:857-862, 1992
30. JAFFA A A, RUST PF, MAYFIELD RK: Kinin, a mediator of diabetes-induced glomerular hyperfiltration. Diabetes 44:156-160, 1995
31. TOOKE JE: Microvascular function in human diabetes: A physiological perspective. Diabetes 44:721-726, 1995
32. VALLON V, WEAD LM, BLANTZ RC: Renal hemodynamics and plasma and kidney angiotensin II in established diabetes mellitus in rats: Effect of sodium and salt restriction. J Am Soc Nephrol 5:1761-1767, 1995
33. LERVANG H-H, JENSEN S, BROCHNER-MORTENSEN J, DITZEL J: Early glomerular hyperfiltration and the development of late nephropathy in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 31:723-729, 1988
34. KENNEFICK TM, OYAMA TT, THOMPSON MM, VORA JP, ANDERSON S: Enhanced renal sensitivity to angiotensin actions in diabetes mellitus in the rat. Am J Physiol 271:F595-F602, 1996
35. ARIMA S, ITO S, OMATA K, TAKEUCHI K, ABE K: High glucose augments angiotensin II action by inhibiting NO synthesis in in vitro microperfused rabbit afferent arterioles. Kidney Int 48:683-689, 1995
36. ANDERSON S, JUNG FF, INGELFINGER JR: Renal renin-angiotensin system in diabetes: Functional, immunohistochemical, and molecular biological correlations. Am J Physiol 265:F477-F486, 1993
37. 2 receptor activation on intracellular calcium, cell proliferation, and extracellular collagen secretion in mesangial cells from normal and diabetic rats. Can J Physiol Pharmacol 73:848-853, 1995
38. VORA JP, OYAMA TT, THOMPSON MM, ANDERSON S: Interactions of the kallikrein-kinin and renin-angiotensin systems in experimental diabetes. Diabetes 46:107-112, 1997
39. JAFFA AA, MILLER DH, BAILEY GS, CHAD J, MARGOLIUS HS, MAYFIELD RK: Abnormal regulation of renal kallikrein in experimental diabetes: Effects of insulin on prokallikrein synthesis and activation. J Clin Invest 80:1651-1659, 1987
40. KOMERS R, COOPER ME: Acute renal hemodynamic effects of ACE inhibition in diabetic hyperfiltration: Role of kinins. Am J Physiol 268:F588-F594, 1995
41. 2 kinin receptor antagonists in diabetic mice. Can J Physiol Pharmacol 74:586-589, 1996
42. PIEPER GM, DONDLINGER L: Glucose elevations alter bradykinin-stimulated intracellular calcium accumulation in cultured endothelial cells. Cardiovasc Res 34:169-178, 1997
43. KOZIK A, MOORE RB, POTEMPA J, IMAMURA T, RAPALA-KOZIK M, TRAVIS J: A novel mechanism for bradykinin production at inflammatory sites: Diverse effects of a mixture of neutrophil elastase and mast cell tryptase versus tissue and plasma kallikreins on native and oxidized kininogens. J Biol Chem 273:33224-33229, 1998
44. CHEN LM, SONG Q, CHAO L, CHAO J: Cellular localization of tissue kallikrein and kallistatin mRNAs in human kidney. Kidney Int 48:690-697, 1995
45. BROWN L, WALL D, MARCHANT C, SERNIA C: Tissue-specific changes in angiotensin II receptors in streptozotocin-diabetic rats. J Endocrinol 154:355-362, 1997
46. MIZUIRI S, KOBAYASHI T, YOSHIKAWA H, MIYAGI M, TANEGASHIMA M, SAKAI K, HAYASHI I, FUSHIMI T, HASEGAWA A: Renal angiotensin-converting enzyme localization in diabetic rats and the effect of low protein diet. Nephron 76:186-191, 1997
47. BJÖRCK S, AURELL M, BRESÄTER L-E, HERLITZ H, WELIN L, WIKSTRAND J: Renal sensitivity to angiotensin II in type 1 diabetes. Scand J Urol Nephrol 24:267-273, 1990.